Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 15Breast Neoplasms 7Sarcoma 5Neoplasm Metastasis 4Carcinoma, Ovarian Epithelial 4Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multi-centric Castleman's Disease 2Hodgkin Disease 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Osteosarcoma 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1

Interventions

Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Doxorubicin 3CTLA-4 Antigen 3Biopsy 3talimogene laherparepvec 1peposertib 1pazopanib 1liposomal doxorubicin 1fludarabine 1cabozantinib 1aldesleukin 1X-Rays 1Trabectedin 1Ifosfamide 1Histamine H2 Antagonists 1Famotidine 1Dactinomycin 1Cyclophosphamide 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × liposomal doxorubicin × 90 days × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡